Literature DB >> 3427041

Primary structure of tetranectin, a plasminogen kringle 4 binding plasma protein: homology with asialoglycoprotein receptors and cartilage proteoglycan core protein.

J Fuhlendorff1, I Clemmensen, S Magnusson.   

Abstract

Tetranectin binds to plasminogen and to isolated kringle 4 [Clemmensen, I., Petersen, L. C., & Kluft, C. (1986) Eur. J. Biochem. 156, 327-333], apparently to its lysine-binding site. Each of the four identical chains consists of 181 amino acid residues. The three intrachain disulfide bonds connect Cys residues 50-60, 77-176, and 152-168. The tetranectin sequence is homologous (17-24% identical positions) with those parts of the asialoglycoprotein receptor family that are considered to be extracellular. Tetranectin has no structures corresponding to those parts of the receptors considered to be intracellular and membrane anchoring. The sequence of tetranectin is also homologous (22-23% identical positions) with the C-terminal globular domain of the core protein of the cartilage proteoglycan. All six Cys residues in tetranectin are located at positions that are also Cys residues in this proteoglycan. Therefore, a plausible disulfide bond pattern can now be proposed for both the asialoglycoprotein receptors and the C-terminal domain of the proteoglycan core protein. No covalently bound carbohydrate has been found.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3427041     DOI: 10.1021/bi00395a027

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  Cancer-associated fibroblasts promote colorectal cancer progression by secreting CLEC3B.

Authors:  Hui-Fang Zhu; Xu-Hui Zhang; Chuan-Sha Gu; Yan Zhong; Ting Long; Yi-Dan Ma; Zhi-Yan Hu; Zu-Guo Li; Xiao-Yan Wang
Journal:  Cancer Biol Ther       Date:  2019-03-20       Impact factor: 4.742

2.  Tetranectin immunoreactivity in normal human tissues. An immunohistochemical study of exocrine epithelia and mesenchyme.

Authors:  L Christensen; I Clemmensen
Journal:  Histochemistry       Date:  1989

3.  Tetranectin, a trimeric plasminogen-binding C-type lectin.

Authors:  T L Holtet; J H Graversen; I Clemmensen; H C Thøgersen; M Etzerodt
Journal:  Protein Sci       Date:  1997-07       Impact factor: 6.725

4.  Tetranectin in slow intra- and extrafusal chicken muscle fibers.

Authors:  X Xu; B Gilpin; K Iba; A Maier; E Engvall; R Albrechtsen; U M Wewer
Journal:  J Muscle Res Cell Motil       Date:  2001       Impact factor: 2.698

5.  The heparin-binding site in tetranectin is located in the N-terminal region and binding does not involve the carbohydrate recognition domain.

Authors:  R H Lorentsen; J H Graversen; N R Caterer; H C Thogersen; M Etzerodt
Journal:  Biochem J       Date:  2000-04-01       Impact factor: 3.857

6.  Mice with a targeted deletion of the tetranectin gene exhibit a spinal deformity.

Authors:  K Iba; M E Durkin; L Johnsen; E Hunziker; K Damgaard-Pedersen; H Zhang; E Engvall; R Albrechtsen; U M Wewer
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

7.  Differences in tetranectin immunoreactivity between benign and malignant breast tissue.

Authors:  L Christensen; I Clemmensen
Journal:  Histochemistry       Date:  1991

8.  Human pancreatitis-associated protein. Messenger RNA cloning and expression in pancreatic diseases.

Authors:  B Orelle; V Keim; L Masciotra; J C Dagorn; J L Iovanna
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

9.  Primary structure of a protein isolated from reef shark (Carcharhinus springeri) cartilage that is similar to the mammalian C-type lectin homolog, tetranectin.

Authors:  P J Neame; C N Young; J T Treep
Journal:  Protein Sci       Date:  1992-01       Impact factor: 6.725

10.  Comparative study of tetranectin levels in serum and synovial fluid of patients with rheumatoid arthritis, seronegative spondylarthritis and osteoarthritis.

Authors:  E F Kamper; L T Kopeikina; P Trontzas; N C Kyriazis; G Vaiopoulos; J Stavridis
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.